| Symbol | AQST |
|---|---|
| Name | AQUESTIVE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 30 TECHNOLOGY DRIVE, WARREN, New Jersey, 07059, United States |
| Telephone | +1 908 941-1900 |
| Fax | — |
| — | |
| Website | https://www.aquestive.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001398733 |
| Description | Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States. Additional info from NASDAQ: |
Barber Daniel 🔴 sold 25.0K shares of Aquestive Therapeutics, Inc. (AQST) at $4.03 Transaction Date: Jul 15, 2026 | Filing ID: 008663
Read more📋 Daniel Barber (Officer) plans to sell 25K shares of Aquestive Therapeutics, Inc. (at $4.04 each, total $101K) Filed: Jul 15, 2026 | ID: 007131
Read moreKrop Julie 🟡 adjusted position in 25.0K shares (1 derivative) of Aquestive Therapeutics, Inc. (AQST) at $5.02 Transaction Date: Jun 23, 2026 | Filing ID: 007677
Read more📋 JULIE KROP (Director) plans to sell 25K shares of Aquestive Therapeutics, Inc. (at $4.72 each, total $118K) Filed: Jun 23, 2026 | ID: 006421
Read moreBarber Daniel 🔴 sold 25.0K shares of Aquestive Therapeutics, Inc. (AQST) at $4.16 Transaction Date: Jun 15, 2026 | Filing ID: 007511
Read more📋 Daniel Barber (Officer) plans to sell 25K shares of Aquestive Therapeutics, Inc. (at $4.17 each, total $104K) Filed: Jun 15, 2026 | ID: 006103
Read moreMORRIS TIMOTHY E 🟢 acquired 50.5K shares (1 derivative) of Aquestive Therapeutics, Inc. (AQST) at $3.99 Transaction Date: Jun 10, 2026 | Filing ID: 007399
Read moreKrop Julie 🟢 acquired 50.5K shares (1 derivative) of Aquestive Therapeutics, Inc. (AQST) at $3.99 Transaction Date: Jun 10, 2026 | Filing ID: 007398
Read moreJenkins Abigail L. 🔴 sold 50.5K shares (1 derivative) of Aquestive Therapeutics, Inc. (AQST) at $3.99 Transaction Date: Jun 10, 2026 | Filing ID: 007397
Read moreCochran John 🟢 acquired 50.5K shares (1 derivative) of Aquestive Therapeutics, Inc. (AQST) at $3.99 Transaction Date: Jun 10, 2026 | Filing ID: 007396
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07703982 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of DESF … | Phase1 | Allergic Reaction | Completed | 2024-12-26 | 2025-05-21 | ClinicalTrials.gov |
| NCT06527937 | Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome | Phase2 | Allergic Reaction | Completed | 2024-07-17 | 2024-10-13 | ClinicalTrials.gov |
| NCT03953820 | Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study | Phase1 | Epilepsy | Completed | 2019-04-13 | 2019-07-31 | ClinicalTrials.gov |
| NCT03679975 | Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Scle… | Phase2 | Amyotrophic Lateral Sclerosis | Terminated | 2018-04-04 | 2018-12-21 | ClinicalTrials.gov |
| NCT03457753 | Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Scler… | Phase2 | ALS | Withdrawn | 2018-03-01 | 2018-03-27 | ClinicalTrials.gov |
| NCT03428360 | Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Ep… | Phase3 | Epilepsy | Completed | 2018-01-23 | 2020-06-25 | ClinicalTrials.gov |
| NCT03222349 | Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Su… | Phase2 | Epilepsy | Completed | 2017-08-31 | 2020-03-11 | ClinicalTrials.gov |
| NCT03179891 | Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-P… | Phase2 | Epilepsy | Completed | 2017-05-25 | 2018-12-21 | ClinicalTrials.gov |
| NCT01220167 | Three-way Crossover Study Comparing Ondansetron ODFS Administered With and With… | Phase1 | Healthy Participants | Completed | 2008-08-01 | 2008-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| DESF | Other | Phase PHASE1 | Allergic Reaction | COMPLETED | NCT07703982 |
| Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT03428360 |
| Riluzole Oral Soluble Film | Other | Phase PHASE2 | ALS | WITHDRAWN | NCT03457753 |
| Diastat® Rectal Gel (Valeant Pharmaceuticals USA) | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT03953820 |
| Diazepam Buccal Film | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT03953820 |
| Riluzole Oral Soluble film (ROSF) 50 mg | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT03679975 |
| Zofran ODT (ondansetron 8 mg) without water | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT01220167 |
| Ondansetron 8 mg ODFS with water | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT01220167 |
| Ondansetron 8 mg ODFS without water | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT01220167 |
| Diazepam Buccal Film 12.5 mg | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT03179891 |
| Diazepam Buccal Film | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT03222349 |
| Epinephrine Injection | Other | Phase PHASE2 | Allergic Reaction | COMPLETED | NCT06527937 |
| DESF | Other | Phase PHASE2 | Allergic Reaction | COMPLETED | NCT06527937 |
| Epinephrine Injection | DRUG | Phase PHASE2 | Allergic Reaction | COMPLETED | NCT06527937 |
| DESF | DRUG | Phase PHASE2 | Allergic Reaction | COMPLETED | NCT06527937 |
| Diastat® Rectal Gel (Valeant Pharmaceuticals USA) | DRUG | Phase PHASE1 | Epilepsy | COMPLETED | NCT03953820 |
| Riluzole Oral Soluble film (ROSF) 50 mg | DRUG | Phase PHASE2 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT03679975 |
| Riluzole Oral Soluble Film | DRUG | Phase PHASE2 | ALS | WITHDRAWN | NCT03457753 |
| Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category | DRUG | Phase PHASE3 | Epilepsy | COMPLETED | NCT03428360 |
| Diazepam Buccal Film | DRUG | Phase PHASE1 | Epilepsy | COMPLETED | NCT03953820 |
| Diazepam Buccal Film 12.5 mg | DRUG | Phase PHASE2 | Epilepsy | COMPLETED | NCT03179891 |
| Zofran ODT (ondansetron 8 mg) without water | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT01220167 |
| Ondansetron 8 mg ODFS with water | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT01220167 |
| Ondansetron 8 mg ODFS without water | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT01220167 |